European Commission's Scientific Committee Sets Out Five-Year Focus For Medical Devices
This article was originally published in SRA
Executive Summary
The use of nanomaterials and endocrine disruptors in medical devices are among the main work items for the European Commission's Scientific Committee on Health Environmental and Emerging Risks over its next, five-year term (2016-2021), it emerged at the inaugural meeting of the newly created committee on April 28-291.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.